SCHEMBL6237723

SCHEMBL6237723

CCCS(=O)(=O)NC1CCC=C1c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 7/20 0.47
FDFT1 P37268 1/20 0.46
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ADAMTS4 O75173 1/20 0.41
MMP13 P45452 1/20 0.41
UCHL1 P09936 1/20 0.40
USP30 Q70CQ3 1/20 0.40
ELOVL6 Q9H5J4 1/20 0.40
PRMT5 O14744 1/20 0.39
GSTP1 P09211 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA4 P22748 1/20 0.39
CA5A P35218 1/20 0.39
CA7 P43166 1/20 0.39
CA9 Q16790 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6240545 0.87 ADAM17 (0.40) ARFDFT1ADAMTS4MMP13ELOVL6
SCHEMBL6243811 0.85 PSEN1 (0.45) RAB9ASMN1; SMN2MMP13MEN1KMT2A
SCHEMBL6237718 0.84 FDFT1 (0.49) ARFDFT1NPC1HPGDRAB9A
SCHEMBL6239997 0.83 CYP11B1 (0.36) NPC1RAB9ACA12CA1CA2
SCHEMBL6242859 0.82 SLC6A9 (0.40) HPGDMEN1CYP1A2KMT2A
SCHEMBL6240738 0.81 ADAM17 (0.37) ARFDFT1ADAMTS4MMP13ELOVL6
SCHEMBL6242245 0.81 CYP11B1 (0.40) MEN1KMT2A
SCHEMBL6242490 0.80 ALDH1A1 (0.47) NPC1RAB9AMEN1CYP1A2KMT2A
SCHEMBL6246324 0.78 PSEN1 (0.43) SMN1; SMN2MMP13MEN1KMT2A
SCHEMBL6241430 0.78 CYP11B1 (0.40) SMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP claimed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US claimed
EP-1395550-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2004-03-10 EP claimed
WO-2002098847-A1 CYCLOALKENYLSULFONAMIDE DERIVATIVES ELI LILLY AND COMPANY (US) 2002-12-12 WO claimed
EP-1395550-B1 CYCLOALKENYLSULFONAMIDE DERIVATIVES LILLY CO ELI (US) 2005-06-29 EP disclosed
US-20040157817-A1 Cycloalkenylsulfonamide derivatives CANTELL BUDDY EUGENE (US) 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157817-A1 Cycloalkenylsulfonamide derivatives GRIN2B, GRIN2A, GRIN1 AR 3477/4885FDFT1 1106/4885NPC1 508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.